NCT05161208View on ClinicalTrials.gov

OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

July 25, 2022

Study Completion Date

July 25, 2022

Conditions

Dry Eye

Interventions

DRUG

OC-01 (varenicline 0.6mg/ml) Nasal Spray

Intranasal delivery of OC-01 nasal spray twice daily (BID)

DRUG

Placebo (vehicle) nasal spray

Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)

Trial Locations (1)

10022

Center for Ophthalmic and Vision Recearch, New York

All Listed Sponsors

lead

Center for Ophthalmic and Vision Research, LLC

OTHER

NCT05161208 - OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers | Biotech Hunter | Biotech Hunter